Interference of Chk2 reverses chemo-resistance of breast cancer initiating cells

doi:10.3877/cma.j.issn.1674-0793.2011.03.005

Abstract

Abstract:

Objective

To find out the mechanism responsibles for the chemo-resistance of breast cancer initiating cells.

Methods

MCF-7 and Adriamycin-resistant MCF-7 (AdrR/MCF-7) were obtained. Mammospheres formation efficiency were caculated to evaluate self-renewal capacity. The proportion of CD44⁺/CD24^- cells and side-population was tested by FACS. The single cell gel electrophoresis(SCEG) was used to test the DNA damage.

Results

Compared with chemo-sensitive MCF-7, AdrR/MCF-7 enriched higher proportion of cancer initiating cells, repaired chemo-induced DNA damage more efficiently, which was associated with activation of Chk2. Interfering activation of Chk2 reduced the capacity of DNA damage repair of breast cancer cells and resensitized them to chemotherapy.

Conclusions

The chemo-resistance of breast cancer initiating cells is related to enhanced capacity of DNA damage repair, which is regulated by activation of Chk2.

Key words: Breast cancer, Initiating cells, DNA damage, DNA repair, Chemo-resistance, Chk2

Neng-yong OUYANG, Chang GONG, He-rui YAO. Interference of Chk2 reverses chemo-resistance of breast cancer initiating cells[J]. Chinese Archives of General Surgery(Electronic Edition), 2011, 05(03): 198-202.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2011.03.005

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2011/V05/I03/198

Figures/Tables 3

References 17

1	Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood, 2002, 99(2): 507-512.
2	Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refra ctory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol, 2004, 22(6): 1078-1086.
3	Bao S, Wu Q, Roger E, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444(6): 756-760.
4	Yu F, Yao H, Zhu P, et al. let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell, 2007, 131(6): 1109-1123.
5	Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 2003, 100(7): 3983-3988.
6	Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2⁺ and ABCG2^- cancer cells are similarly tumorigenic. Cancer Res, 2005, 65(14): 6207-6219.
7	Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res, 2005, 65(13): 5506-5511.
8	Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nature Rev Cancer, 2004, 4(3): 216-225.
9	Laurent A, Nayanta S, Lan C, et al. CHK2 Kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nature Rev Cancer, 2007, 7(12): 925-936.
10	Chen Y, Sanchez Y. Chk1 in the DNA damage response: conserved roles from yeasts to mammals. DNA Repair, 2004, 3(8-9): 1025-1032.
11	Li J, Taylor IA, Lioyd J, et al. Chk2 oligomerization studied by phosphopeptide ligation: implications for regulation and phosphodependent interactions. J Biol Chem, 2008, 283(51): 36 019-36 130.
12	Olsen BB, Larsen MR, Boldyreff B, et al. Exploring the intramolecular phosphorylation sites in human Chk2. Mutat Res, 2008, 646(1-2): 50-59.
13	Huang M, Miao ZH, Zhu H, et al. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther, 2008, 7(6): 1440-1449.
14	Zhuang J, Zhang J, Willers H, et al. Checkpoint kinase 2 mediated hosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res, 2006, 66(3): 401-1408.
15	Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol, 2009, 21(2): 245-255.
16	Zhang W, Poh A, Fanous AA, et al. DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2. Cell Cycle, 2008, 7(11): 1668-1677.
17	Roos WP, Kaina B. Roos and Bernd Kaina. DNA damage-induced cell death by apoptosis. Trends Mol Med, 2006, 12(9): 440-450.

[1]	Xu Zhang, Jianping Xu, Dongming Su, Caifen Wang, Dali Wang, Wenzhi Zhang. Contrast-enhanced ultrasound features of male breast masses [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 854-859.
[2]	Hua Shao, Ziyue Na, Hui Jing, Bo Li, Qiucheng Wang, Wen Cheng. Value of preoperative percutaneous contrast-enhanced ultrasound in diagnosis of axillary sentinel lymph node metastasis and burden in breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 849-853.
[3]	Meiwu Zhang, Shuyi Lyu, Xiaoxiang Fan, Luhui Zhuang, Yuqin Qiu, Baisong Zhang, Yan Zhang. Clinical value of ultrasound-guided aspiration combined with hypertonic glucose flushing in treatment of postoperative subcutaneous effusion in patients with breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(03): 327-331.
[4]	Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[5]	bing Feng, Qiuguo Zou, Zhenbo Liang, Yanming Lu, Yi Zeng, Shumiao Wu. Clinical study of ultrasonic signs and molecular biological indicators of senile non-specific invasive breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 48-51.
[6]	Jia Wang, Baoliang Guo, Shan Wang, Dianlong Zhang, Mijia Wang, Tianyang Zhou, Jianguo Zhang, Feng Jin. Interpretation of clinical practice guidelines for diagnosis and treatment of de novo stage Ⅳ breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 250-254.
[7]	Yating Wu, Shenghang Zhang, Shuiliang Wang. Research progress in the role of dysregulated RNA m⁶A modification in breast cancer metastasis [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(01): 45-52.
[8]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[9]	Fei Liu, Yingxin Wang, Xing Ma, Ling Xin, Yuanjia Cheng, Qian Liu, Yue Wang, Junjun Zhang. Different conductive media for intracavitary electrocardiogram-guided arm port implantation among breast cancer patients: a randomized controlled trial [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 760-764.
[10]	Jiayi Li, Hong Zhang, Jingming Ye, Yinhua Liu, Ling Xu, Shuang Zhang. Androgen receptor: discoveries in breast cancer clinical practice [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1031-1038.
[11]	Fan Yang, Hong Zhang, Jiay Li, Ling Xin, Hongyu Xiang, Qian Liu, Yuanjia Cheng, Jingming Ye, Xuening Duan, Yinhua Liu, Ling Xu, Shuang Zhang. Characteristics of CK5/6 expression in early triple-negative breast cancer: correlation with prognosis and efficacy of neoadjuvant chemotherapy [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1081-1088.
[12]	Exian Mou, Hao Wang, Li Xia, Juan Li, Shiyan Zeng, Miao Yu, Junjie Li, Jia Xu, Purong Zhang, Man Lu, Hui Li, Shiwei Liu. Contrast-enhanced ultrasonography combined with blue dye for sentinel lymph node biopsy in neoadjuvant-treated HER2-positive or triple-negative breast cancer with initially biopsy-proven nodal metastasis [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1068-1074.
[13]	Junwei Cui, Yinhua Liu, Xiaoling Liu, Yibing Hu, Hui Hu. Efficacy and safety of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1062-1067.
[14]	Yilin Xu, Hong Lu, Xuejing Liu, Yujuan Hao, Ziling Yu, Ying Zhu. Value of imaging progress in precise axillary treatment of breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1054-1061.
[15]	Zeyu Cai, Huimin Lan, Ting Yu, Hui Luo. The study based on Ti₃C₂ loaded with doxorubicin and combined with photothermal therapy for inhibiting the proliferation of breast cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(02): 140-145.

Please choose a citation manager

Content to export